Comprehensive Clinical Development

Aepodia is specialized in the strategy and delivery of early drug and Medical Devices development and provides scientific consultancy as well as operational support across various indications including but not limited to CNS, Endocrinology, Metabolic Disease, Oncology...

Our very experienced clinical trial team can implement, manage and execute clinical trials, by offering “ad hoc” or “full services” support to complement the sponsor’s internal team (e.g., Regulatory Strategy, Study design, Project Coordination, Monitoring, Competent Authority Submission, Site Selection/Assessment/Management, Medical Writing …).

In addition to traditional services, Aepodia conducts preclinical and clinical Due Diligence to facilitate your out-licensing or in-licensing activities.

Founded in 1997, Ergomed plc is a global provider of high-quality services to the biopharmaceutical industry, spanning all phases of clinical trials, post-approval pharmacovigilance, and medical information. Ergomed’s fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and Ergomed Clinical Research, a complete, global Phase I-IV clinical development and trial management services with a strong heritage in the development of drugs in rare diseases and oncology.

• 1 300+ highly qualified professionals
• Global full-service CRO
• 24+ years of experience
• Therapeutic specialization in oncology
• Strong expertise in rare disease trials
• Robust clinical safety system
• Choice of leading drug safety databases

Our key services include:
• Clinical Research Services
• Pharmacovigilance
• Medical Information
• Regulatory
• Medical Writing
• Site Management
• Study Physician Support
• Biostatistics
• Patient Study Support

IQVIA Biotech delivers flexible, tailored, clinical and commercial solutions designed for biotech and biopharma companies. From planning, through trial design and delivery, and commercialization, IQVIA Biotech brings simplified operating procedures, specialized, therapeutically-aligned teams, and advanced data science to provide a more agile way for our customers to reach their drug development and commercialization milestones.

From site access to patient recruitment to drug delivery, the impact of COVID-19 on clinical development is widespread. IQVIA Biotech is helping to ensure our customers can continue to study disease, help patients and continue innovation -- during this crisis and beyond. Visit our website to learn more about our COVID-19 clinical trial continuity solutions.

RenaSci provides an integrated blend of consultancy and preclinical experimental services to the pharmaceutical industry. Our clients include pharma, biotech, virtual companies and healthcare investors worldwide. We specialise in abuse and dependence testing and in the therapeutic areas of CNS and metabolic disorders.

Consultancy is provided on all aspects of drug discovery, preclinical and clinical development, regulatory approval, intellectual property protection and market positioning. We have facilitated more than 30 candidates into clinical development and 10 drugs to the market.

RenaSci is the leading preclinical service provider for abuse/dependence testing. We offer all of the mandatory procedures required for regulatory approval: intravenous self-administration, drug discrimination and tolerance/dependence studies. We can also evaluate novel treatments for drug dependence. We are GLP-accredited. Our studies are accepted by the FDA and EMA and have supported many recent US and European drug approvals.

We employ a wide range of techniques to determine the mode of action, efficacy and side-effect profile of centrally-acting drugs including: ex vivo receptor binding, intracerebral microdialysis and behavioural models such as conditioned avoidance responding, prepulse inhibition of acoustic startle, reversal of psychostimulant-induced hyperactivity, catalepsy testing, antipsychotic-induced weight gain and a model of binge-eating disorder.

We have established a number of models of obesity, diabetes and related conditions. These include DIO mice and rats, the STZ/high-fat diet model of diabetes, dietary-induced NASH and models to assess diabetic complications and chronic kidney disease. Studies can include measurement of body weight, food and water intake, glycaemic control, body composition, metabolic rate, a variety of parameters in blood, plasma and urine, liver lipids and histopathology.

For further information please see our website.

Allphase Clinical Research is a full-service clinical development company providing clinical trial management services, including regulatory affairs, project management, clinical monitoring, data management, quality assurance auditing, drug safety, and medical writing. Allphase provides Phase I to IV support throughout a wide range of therapeutic areas, with a predominant focus in oncology, CNS, and critical care diseases.

Allphase provides integrative and strategic clinical trial services that allow our international partners to realize the advantages of conducting clinical trails in North America, while reinforcing therir global development cpabilities.